These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 670400)
1. Glucose and alanine metabolism in children with maple syrup urine disease. Haymond MW; Ben-Galim E; Strobel KE J Clin Invest; 1978 Aug; 62(2):398-405. PubMed ID: 670400 [TBL] [Abstract][Full Text] [Related]
2. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine. Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005 [TBL] [Abstract][Full Text] [Related]
3. A chemically-induced acute model of maple syrup urine disease in rats for neurochemical studies. Bridi R; Fontella FU; Pulrolnik V; Braun CA; Zorzi GK; Coelho D; Wajner M; Vargas CR; Dutra-Filho CS J Neurosci Methods; 2006 Sep; 155(2):224-30. PubMed ID: 16530844 [TBL] [Abstract][Full Text] [Related]
4. Domino liver transplantation in maple syrup urine disease. Khanna A; Hart M; Nyhan WL; Hassanein T; Panyard-Davis J; Barshop BA Liver Transpl; 2006 May; 12(5):876-82. PubMed ID: 16628687 [TBL] [Abstract][Full Text] [Related]
5. Definition of the mutation responsible for maple syrup urine disease in Poll Shorthorns and genotyping Poll Shorthorns and Poll Herefords for maple syrup urine disease alleles. Dennis JA; Healy PJ Res Vet Sci; 1999 Aug; 67(1):1-6. PubMed ID: 10425233 [TBL] [Abstract][Full Text] [Related]
6. Assessment of whole body L-leucine oxidation by noninvasive L-[1-13C]leucine breath tests: a reappraisal in patients with maple syrup urine disease, obligate heterozygotes, and healthy subjects. Schadewaldt P; Bodner A; Brösicke H; Hammen HW; Wendel U Pediatr Res; 1998 May; 43(5):592-600. PubMed ID: 9585004 [TBL] [Abstract][Full Text] [Related]
8. Intrahippocampal administration of the branched-chain alpha-hydroxy acids accumulating in maple syrup urine disease compromises rat performance in aversive and non-aversive behavioral tasks. Vasques Vde C; Brinco F; Wajner M J Neurol Sci; 2005 May; 232(1-2):11-21. PubMed ID: 15850577 [TBL] [Abstract][Full Text] [Related]
9. Evidence of common ancestry for the maple syrup urine disease (MSUD) Y438N allele in non-Mennonite MSUD patients. Love-Gregory LD; Grasela J; Hillman RE; Phillips CL Mol Genet Metab; 2002 Jan; 75(1):79-90. PubMed ID: 11825067 [TBL] [Abstract][Full Text] [Related]
10. Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease. Jouvet P; Jugie M; Rabier D; Desgrès J; Hubert P; Saudubray JM; Man NK Intensive Care Med; 2001 Nov; 27(11):1798-806. PubMed ID: 11810125 [TBL] [Abstract][Full Text] [Related]
11. Protein and leucine metabolism in maple syrup urine disease. Thompson GN; Bresson JL; Pacy PJ; Bonnefont JP; Walter JH; Leonard JV; Saudubray JM; Halliday D Am J Physiol; 1990 Apr; 258(4 Pt 1):E654-60. PubMed ID: 2185648 [TBL] [Abstract][Full Text] [Related]
12. [Heterogeneity of leucinosis. Correlations between clinical manifestations, protein tolerance and enzyme deficiency]. Saudubray JM; Amédée-Manesme O; Munnich A; Ogier H; Depondt E; Charpentier C; Coudé FX; Rey F; Frézal J Arch Fr Pediatr; 1982 Dec; 39 Suppl 2():735-40. PubMed ID: 6897702 [TBL] [Abstract][Full Text] [Related]
13. Molecular basis of intermittent maple syrup urine disease: novel mutations in the E2 gene of the branched-chain alpha-keto acid dehydrogenase complex. Tsuruta M; Mitsubuchi H; Mardy S; Miura Y; Hayashida Y; Kinugasa A; Ishitsu T; Matsuda I; Indo Y J Hum Genet; 1998; 43(2):91-100. PubMed ID: 9621512 [TBL] [Abstract][Full Text] [Related]
14. Clearance of branched chain amino acids by peritoneal dialysis in maple syrup urine disease. McMahon Y; MacDonnell RC Adv Perit Dial; 1990; 6():31-4. PubMed ID: 1982835 [TBL] [Abstract][Full Text] [Related]
15. [Compliance of the diet restricted with leucine, isoleucine and valine in maple syrup urine disease (MSUD) children]. Kowalik A; Narojek L; Sykut-Cegielska J Rocz Panstw Zakl Hig; 2007; 58(1):95-101. PubMed ID: 17711097 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification. Heldt K; Schwahn B; Marquardt I; Grotzke M; Wendel U Mol Genet Metab; 2005 Apr; 84(4):313-6. PubMed ID: 15781191 [TBL] [Abstract][Full Text] [Related]
17. Intermittent maple syrup urine disease: two case reports. Axler O; Holmquist P Pediatrics; 2014 Feb; 133(2):e458-60. PubMed ID: 24394677 [TBL] [Abstract][Full Text] [Related]
18. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Hoffmann B; Helbling C; Schadewaldt P; Wendel U Pediatr Res; 2006 Jan; 59(1):17-20. PubMed ID: 16326996 [TBL] [Abstract][Full Text] [Related]
19. Acute illness in maple syrup urine disease: dynamics of protein metabolism and implications for management. Thompson GN; Francis DE; Halliday D J Pediatr; 1991 Jul; 119(1 Pt 1):35-41. PubMed ID: 2066856 [TBL] [Abstract][Full Text] [Related]
20. Maple syrup urine disease: case report of 2 Thai infants. Chiemchanya S; Suthutvoravut U; Visudhiphan P J Med Assoc Thai; 1989 Jan; 72 Suppl 1():116-20. PubMed ID: 2732631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]